Citation Impact
Citing Papers
Cytokine activation induces human memory-like NK cells
2012
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
2013 StandoutNobel
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Education of human natural killer cells by activating killer cell immunoglobulin-like receptors
2009
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
2002
Cutting Edge: KIR Antisense Transcripts Are Processed into a 28-Base PIWI-Like RNA in Human NK Cells
2010
Cutting Edge: NKG2ChiCD57+ NK Cells Respond Specifically to Acute Infection with Cytomegalovirus and Not Epstein–Barr Virus
2014
Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands
2007
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
2007
Herceptin: mechanisms of action and resistance
2005
Controlling timing and location in vaccines
2020
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Mechanisms, regulation and functions of the unfolded protein response
2020 Standout
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
2014 Standout
Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model
2008
Complement and cellular cytotoxicity in antibody therapy of cancer
2008
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer
2015
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
2007 Standout
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Natural killer cell–directed therapies: moving from unexpected results to successful strategies
2008
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
2006
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
2019 Standout
Regulation of cytoskeletal dynamics by redox signaling and oxidative stress: implications for neuronal development and trafficking
2015
In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application
2016
Trastuzumab: triumphs and tribulations
2007
NK cell development, homeostasis and function: parallels with CD8+ T cells
2011
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
BNIP3- and BNIP3L-Mediated Mitophagy Promotes the Generation of Natural Killer Cell Memory
2015
HLA-C Antigen Mismatch Is Associated with Worse Outcome in Unrelated Donor Peripheral Blood Stem Cell Transplantation
2010
Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals
2015
EGF–ERBB signalling: towards the systems level
2006 Standout
Transcription Factor IRF8 Orchestrates the Adaptive Natural Killer Cell Response
2018
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery
2021 StandoutNobel
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Engineering interferons and interleukins for cancer immunotherapy
2022
Application potential of toll-like receptors in cancer immunotherapy
2016
Functions of natural killer cells
2008 Standout
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold – A Potential Therapeutic Intervention for Skin Diseases
2016 StandoutNobel
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
2015
Targeting macrophages: therapeutic approaches in cancer
2018
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Costimulatory Molecule DNAM-1 Is Essential for Optimal Differentiation of Memory Natural Killer Cells during Mouse Cytomegalovirus Infection
2014
Emerging targets in cancer immunotherapy
2017
Graft-versus-host disease
2009 Standout
Human Cytomegalovirus Drives Epigenetic Imprinting of the IFNG Locus in NKG2Chi Natural Killer Cells
2014
A timeline of tumour-associated macrophage biology
2023
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection
2010
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc
2019
Non-coding RNAs in human disease
2011 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Repair of peroxynitrite damage to tubulin by the thioredoxin reductase system
2004
Cytomegalovirus Infection Drives Avidity Selection of Natural Killer Cells
2019
Prospects for the use of NK cells in immunotherapy of human cancer
2007
Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function
2015
The RAG Recombinase Dictates Functional Heterogeneity and Cellular Fitness in Natural Killer Cells
2014
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
The IPD and IMGT/HLA database: allele variant databases
2014
Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study
2012
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity
2015
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Targeting Toll-like receptors: emerging therapeutics?
2010
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft‐ and transplantation‐related factors
2009
Defining trained immunity and its role in health and disease
2020 Standout
Bispecific antibodies: a mechanistic review of the pipeline
2019
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Comèl-Netherton syndrome defined as primary immunodeficiency
2009
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality
2009
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
2016
Acute Myeloid Leukemia
2015 Standout
Trastuzumab in the management of early and advanced stage breast cancer.
2007
The EMBL-EBI search and sequence analysis tools APIs in 2019
2019 Standout
Ultraviolet B–Induced Maturation of CD11b-Type Langerin− Dendritic Cells Controls the Expansion of Foxp3+ Regulatory T Cells in the Skin
2017 StandoutNobel
Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self
2006
Impact of β2 integrin deficiency on mouse natural killer cell development and function
2011 StandoutNobel
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Cytomegalovirus generates long-lived antigen-specific NK cells with diminished bystander activation to heterologous infection
2014
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
2009
Investigational CD33-targeted therapeutics for acute myeloid leukemia
2018
Graft-versus-leukemia effects of transplantation and donor lymphocytes
2008
Oxidation Proteomics: The Role of Thiol Modifications
2009
Regulation of neuronal development and function by ROS
2018
Modular repeat protein sculpting using rigid helical junctions
2020 StandoutNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Mechanisms of Diabetic Complications
2013 Standout
Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells
2010 StandoutNobel
Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity
2009
Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease
2019
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
2008
IL-12–producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion
2014
Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization
2020 StandoutNobel
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
2008
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor–, granulocyte-macrophage colony-stimulating factor–, and interleukin-3–expressing NOD-SCID IL2Rγnull humanized mice
2011 StandoutNobel
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Innate or Adaptive Immunity? The Example of Natural Killer Cells
2011 StandoutScience
Innate immunity, inflammation and tumour progression: double‐edged swords
2019
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses
2016
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
2017
IL-33 Receptor ST2 Amplifies the Expansion of NK Cells and Enhances Host Defense during Mouse Cytomegalovirus Infection
2015
Works of Sarah Cooley being referenced
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
2016
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
2016
Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
2011
Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37
2018
Prolonged subcutaneous administration of 852A, a novel systemic toll‐like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies
2012
Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu
1999
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
2010
Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
2010
Peroxynitrite Oxidation of Tubulin Sulfhydryls Inhibits Microtubule Polymerization
2002
The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT )
2014
Trispecific Killer Engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion
2015
Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity
2009
A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature
2007
Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen
2012
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
2018
Genotype List String: a grammar for describing HLA and KIR genotyping results in a text string
2013
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL
2019
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
2008
Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation
2015
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT
2007
KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation
2005
Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone
2007
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
2014
First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer
2007
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
2010
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
2013
Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells
2018
Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia
2014